25th January, 2023

The Dy. General Manager (Listing Dept.)
BSE Limited,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

We would like to inform that the Board has at its meeting held today approved, inter-alia, the following:

1) Audited Standalone Financial Results along with audit report thereon and Unaudited Consolidated Financial Results along with the limited review report of the Company for the quarter and nine months ended on 31st December, 2022. The said financial results are enclosed herewith.

   In terms of Regulation 47 of the Listing Regulations, the Company will publish an extract of Unaudited Consolidated Financial Results for the quarter and nine months ended on 31st December, 2022. Both Standalone and Consolidated Financial Results will be available at Company's website www.torrentpharma.com.

   A Press Release on Financial Results which is being submitted to the media is also enclosed herewith.

2) An interim dividend of ₹ 14/- (280 %) per equity share of ₹ 5/- fully paid up. The dividend is expected to be paid / dispatched on or around 14th February, 2023.

The Board meeting commenced at 02:10 pm and concluded at 04:10 pm.

The above is for your information and record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN MAHESHKUMAR TRIVEDI
Digitally signed by CHINTAN MAHESHKUMAR TRIVEDI
Date: 2023.01.25 16:32:06 +05'30'

CHINTAN M. TRIVEDI
COMPANY SECRETARY

Encl : A/a